An anti-Covid protein vaccine developed and manufactured in China, called V-01, has been shown to be effective in protecting against infection caused by the Omicron variant of Sars-CoV-2 in a study conducted in Pakistan and Malaysia of over 10,000 adults over 18. who had received a second dose of inactivated vaccine within the previous 3-6 months. This was announced by LivzonBio, a pharmaceutical company from Guangdong, which developed the product together with the Biophysics Institute of the Chinese Academy of Sciences. Half of the 10,241 enrolled were given a V-01 booster, the other half a placebo. According to preliminary data released by LivzonBio, 110 trial participants were infected with the pandemic coronavirus, 60 of whom infected with Omicron, while sequencing is still underway for the remaining portion. The person-year infection rate in the placebo group was approximately double that of the V-01 group (12.8% vs 6.73%), with vaccine candidate efficacy greater than 61.35% against infection. “A booster dose of V-01 can provide good protection against the Omicron variant,” says LivzonBio, noting that “no safety concerns were found among those who received it.” V-01 is a protein vaccine of recombinant fusion targeted against Rbd, a portion of the Spike protein crucial for binding to the Ace2 receptor of human cells. According to the company, it is easier to produce, as well as to store and transport than others.